Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Common Equity (2010 - 2026)

Innoviva's (INVA) quarterly Common Equity came in at $1.3 billion in Q1 2026, up 107.4% YoY from $646.9 million in Q1 2025, and up 14.39% on a QoQ basis from $1.2 billion in Q4 2025.

Analysis

Innoviva (INVA) Common Equity (2010 - 2026) Analysis & Trends

Innoviva (INVA) has 17 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

  • Quarterly Common Equity rose 107.4% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 107.4% YoY) and the FY2025 annual result came in at $1.2 billion, up 69.69% from the prior year.
  • Common Equity rose to $1.3 billion in Q1 2026, from $1.2 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $552.2 million in Q1 2022.
  • A 5-year average of $727.0 million and a median of $665.5 million in 2024 frame the typical range for Common Equity.
  • Annual changes were most pronounced in 2022 — Common Equity fell 20.74% — and 2026, when it soared 107.4%.
  • Tracing INVA's Common Equity over 5 years: stood at $565.8 million in 2022, then advanced by 19.29% to $675.0 million in 2023, then rose by 2.4% to $691.2 million in 2024, then surged by 69.69% to $1.2 billion in 2025, then advanced by 14.39% to $1.3 billion in 2026.
  • The last three Common Equity figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 20.25 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 31.71 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 8.42 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 6.76 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.61 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 5.17 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.35 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.79 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 757.49 Mn
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn 1.23 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.23 Bn
Mar 31, 2026 1.34 Bn
Dec 31, 2025 1.17 Bn
Sep 30, 2025 1.01 Bn
Jun 30, 2025 714.82 Mn
Mar 31, 2025 646.91 Mn
Dec 31, 2024 691.16 Mn
Sep 30, 2024 668.54 Mn
Jun 30, 2024 665.52 Mn
Mar 31, 2024 703.68 Mn
Dec 31, 2023 674.96 Mn
Sep 30, 2023 627.49 Mn
Jun 30, 2023 555.09 Mn
Mar 31, 2023 561.49 Mn
Dec 31, 2022 565.79 Mn
Sep 30, 2022 641.37 Mn
Jun 30, 2022 565.46 Mn
Mar 31, 2022 552.22 Mn
Dec 31, 2021 525.94 Mn
Sep 30, 2021 491.81 Mn